勃林格殷格翰公司对诊断和治疗慢性阻塞性肺疾病以及重症哮喘患者新方法非常感兴趣。针对慢性阻塞性肺病患者或重症哮喘所造成的呼吸道障碍，他们积极寻求恢复方法并寻找分子靶点开发治疗药物。具体如下：（https://www.innocentive.com/ar/challenge/9933560） Boehringer Ingelheim (the Seeker) is interested in identifying new therapeutic concepts for the treatment of patients with chronic obstructive pulmonary disease (COPD) or severe asthma. The Seeker is specifically searching for molecular targets to develop therapeutic agents for the restoration of the airway epithelial barrier function in patients with COPD or severe asthma. The Seeker is also interested in molecular targets driving the regeneration of the airway epithelium. Submitted solutions that meet the Solution Requirements according to this InnoCentive Challenge Statement will be considered for up to three awards of $15,000 each. However, the Seeker may (i) not award any solution if none of the submitted proposals meets all Solution Requirements or (ii) award only the solution of the highest overall quality with $15,000. The consideration for an award requires the willingness and ability of the Solver to provide the Seeker with a non-exclusive license regarding all intellectual property related to the Challenge according to the terms of the InnoCentive Theroretical (Non-Exclusive-License) Challenge-Specific Agreement. 2. Additional application for Research Funding In addition to consideration for the award(s) Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the submitted solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of the Challenge, and will require the submission of additional information. The decision to fund research will be at the sole discretion of the Seeker. The Challenge according to No. 1 requires only a written proposal. Qualified Solvers can, in addition, apply for Research Funding according to No. 2. Solvers may be awarded for the (i) submitted solution and may be (ii) selected for Research Funding independently of being awarded. In particular, selection of a solution for the award does not automatically lead to a selection for Research Funding.
互联网增值电信业务许可证编号：渝B2-20120028 | 渝ICP备10200070号 互联网药品信息服务资格证：(渝)-经营性-2016-0011 渝公网备：50010801500236
康洲大数据 版权所有 Copyright © 2009-2021 药智网YAOZH.COM All Rights Reserved. 法律顾问：上海锦天城（重庆）律师事务所 程建律师
客户服务热线：400-678-0778 E-mail：firstname.lastname@example.org 商务合作QQ：845146016